{"entity":{"id":"nct05678270","kind":"trial","name":"A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma","aka":[],"tldr":"A phase 2 trial of ICP-192 in biliary tract cancer, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.","summary":"A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma is a phase 2 interventional study registered as NCT05678270 by Beijing InnoCare Pharma Tech Co., Ltd., with 70 participants planned, started 2022-11-15 and due to reach its primary completion in 2026-05. Interventions recorded: ICP-192.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05678270","url":"https://clinicaltrials.gov/study/NCT05678270"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05678270","phase":"2","setting":"A Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of ICP-192 in Subjects With Unresectable or Metastatic Intrahepatic Cholangiocarcinoma With FGFR2 Fusions/Rearrangements Who Have Failed Prior Therapy","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","enrolled":70,"outcomes":[]},"route":"/trials/nct05678270/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"}]}}